Too much success? A booming biotech pipeline will spur intense rivalries — analyst

Over the last 5 years biotech has been booming. And that could pose a big problem for everyone involved. Like others in the industry, Leerink’s Geoffrey Porges hasn’t overlooked evidence that every hot new target in drug discovery quickly attracts a cluster of biopharma companies.